Cartherics, an Australian biotech company developing immune cell therapies, has announced the successful completion of an oversubscribed private financing round, raising over AU$15 million. This funding will primarily support the clinical trial of CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases. Based in Melbourne, Cartherics focuses on developing cell-based immunotherapies for cancer treatment.…
Helaina, a biotechnology company focused on human equivalent bioactive proteins, has announced a $45 million Series B funding round bringing the company’s total equity funding to $83 million. Avidity Partners led the round, with participation from Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity, and Primary Venture Partners, among others. The funding…
U-Ploid, a venture-backed biotech company, has introduced its new platform designed to enhance the quality of older egg cells, a critical factor in increasing the success rates of in vitro fertilization (IVF) for women experiencing age-related infertility. The company’s technology aims to repair decades of accumulated damage in eggs, thereby improving their viability during IVF treatments. Age-related fertility decline affects millions worldwide,…
BoobyBiome, a biotechnology company focused on infant health, has secured a £1.6 million Biomedical Catalyst grant from Innovate UK. The funding will support the testing and scale-up of BoobyBiome’s Synbiotic, a product developed from breast milk to improve gut health in infants. “We are delighted to receive this substantial grant from Innovate UK,” stated Dr. Lydia Mapstone, CEO and Co-founder of BoobyBiome.…
DiaMedica Therapeutics, a clinical-stage biopharmaceutical company focused on novel treatments for severe ischemic diseases, has announced the initiation of a Phase 2 trial for their preeclampsia treatment, DM199. This announcement came alongside their second quarter 2024 financial results and business update. Preeclampsia (PE) is a serious pregnancy complication characterized by high blood pressure and damage to organ systems, often affecting the kidneys…
Seed Health, a company working in microbiome science, has unveiled promising clinical data on their flagship product, VS-01 Vaginal Synbiotic. The findings will be presented at the 2024 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG). This study is the first to demonstrate that a multi-strain vaginal synbiotic can successfully establish a protective and optimal vaginal microbiome, dominated…
Oxolife, a biotech company specializing in female fertility, has announced promising results from a Phase 2 clinical trial of its non-hormonal fertility pill, OXO-001, at the European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting in Amsterdam. The data indicates that OXO-001 significantly improves embryo implantation, pregnancy, and live birth rates in women undergoing in-vitro fertilization (IVF) and intracytoplasmic sperm…
Menarini Silicon Biosystems (MSB) has presented data at the 2024 Fetal Medicine Foundation (FMF) World Congress in Lisbon, Portugal, demonstrating the accuracy of their cell-based non-invasive prenatal testing (NIPT) technology. The study results indicate that their technology can detect fetal genomic abnormalities through a maternal blood draw with high resolution. MSB offers unique rare cell technologies and solutions that provide clinical researchers…
